Aging diastole - root cause for atrial fibrillation and heart failure with preserved ejection fraction

Abstract

The age-related decline in diastolic function can result in heart failure with a preserved ejection fraction (HFpEF) and atrial fibrillation (AF), which are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. In humans, diastolic dysfunction results from structural and functional changes that increasingly impede diastolic filling after midlife. Comorbidities and pathomechanisms that lead to additional increases in cardiac filling pressures accelerate the age-related deterioration in diastolic function. It is, therefore, that targeting the accelerators of diastolic dysfunction holds the most promise in reducing the risk for HFpEF and AF.

Keywords

Heart failure / heart rate / ejection fraction / diastolic function / cardiac filling pressures / cardiac remodeling

References

[1] Laughlin MH.Cardiovascular response to exercise.Am J Physiol1999;277:S244-59

[2] Myers J,Froelicher V,Partington S.Exercise capacity and mortality among men referred for exercise testing.N Engl J Med2002;346:793-801

[3] Yancy CW,Bozkurt B.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation2013;128:e240-327

[4] Heidenreich PA,Aguilar D.2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.J Am Coll Cardiol2022;79:1757-80

[5] Kittleson MM,Amancherla K.2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American college of cardiology solution set oversight committee.J Am Coll Cardiol2023;81:1835-78

[6] Pieske B,de Boer RA.How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).Eur Heart J2019;40:3297-317

[7] Paulus WJ,Sanderson JE.How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European society of cardiology.Eur Heart J2007;28:2539-50

[8] Iwanaga Y,Furuichi S.B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.J Am Coll Cardiol2006;47:742-8

[9] Maisel AS,Nowak RM.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med2002;347:161-7

[10] Horwich TB,Fonarow GC.B-type natriuretic peptide levels in obese patients with advanced heart failure.J Am Coll Cardiol2006;47:85-90

[11] Reddy YNV,Obokata M,Borlaug BA.A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction.Circulation2018;138:861-70 PMCID:PMC6202181

[12] Bluemke DA,Lima JA.The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (multi-ethnic study of atherosclerosis) study.J Am Coll Cardiol2008;52:2148-55 PMCID:PMC2706368

[13] Cheng S,Bluemke DA,Kronmal RA.Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the multi-ethnic study of atherosclerosis.Circ Cardiovasc Imaging2009;2:191-8 PMCID:PMC2744970

[14] Lang RM,Mor-Avi V.Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging.J Am Soc Echocardiogr2015;28:1-39.e14

[15] Zemrak F,Captur G.Left atrial structure in relationship to age, sex, ethnicity, and cardiovascular risk factors: MESA (multi-ethnic study of atherosclerosis).Circ Cardiovasc Imaging2017;10:e005379

[16] La Gerche A, Howden EJ, Haykowsky MJ, Lewis GD, Levine BD, Kovacic JC. Heart failure with preserved ejection fraction as an exercise deficiency syndrome: JACC focus seminar 2/4.J Am Coll Cardiol2022;80:1177-91

[17] Redfield MM.Heart failure with preserved ejection fraction: a review.JAMA2023;329:827-38

[18] Borlaug BA,Sorajja P,Redfield MM.Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.Circ Heart Fail2010;3:588-95 PMCID:PMC3048586

[19] Borlaug BA.Evaluation and management of heart failure with preserved ejection fraction.Nat Rev Cardiol2020;17:559-73

[20] Wolsk E,Thomsen JH.The influence of age on hemodynamic parameters during rest and exercise in healthy individuals.JACC Heart Fail2017;5:337-46

[21] Zierath R,Arthur V.Changes in pulmonary artery pressure late in life: the atherosclerosis risk in communities (ARIC) study.J Am Coll Cardiol2023;82:2179-92

[22] Selby DE,LeWinter MM.Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction.J Am Coll Cardiol2011;58:147-54 PMCID:PMC3147146

[23] Runte KE,Selby DE.Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction.Circ Heart Fail2017;10:e004311 PMCID:PMC5567852

[24] Silverman DN,Lustgarten DL,LeWinter MM.Heart rate-induced myocardial Ca²⁺ retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction.J Am Heart Assoc2020;9:e017215 PMCID:PMC7660766

[25] Meyer M.Diastolic tone-friend and foe of cardiac performance.Circ Heart Fail2023;16:e011307

[26] Reddy YNV,Carter R.Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial.JAMA2023;329:801-9

[27] Molnár AÁ,Dörnyei G.The aging venous system: from varicosities to vascular cognitive impairment.Geroscience2021;43:2761-84 PMCID:PMC8602591

[28] Sorimachi H,Verbrugge FH.Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction.Eur J Heart Fail2021;23:1648-58

[29] Lakatta EG,Pomerance A.Human aging: changes in structure and function.J Am Coll Cardiol1987;10:42A-7A

[30] de la Espriella R,Losito M.Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: size matters. Eur J Heart Fail 2024.

[31] Hieda M,Hearon CM Jr.One-year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction.Circulation2021;144:934-46 PMCID:PMC8849598

[32] Driussi C,Bizzarini E.Structural and functional left ventricular impairment in subjects with chronic spinal cord injury and no overt cardiovascular disease.J Spinal Cord Med2014;37:85-92 PMCID:PMC4066555

[33] Wang CC,Lin CL,Kao CH.Spinal cord injury is associated with an increased risk of atrial fibrillation: a population-based cohort study.Heart Rhythm2016;13:416-23

[34] Yoo JE,Kim B.Increased risk of myocardial infarction, heart failure, and atrial fibrillation after spinal cord injury.J Am Coll Cardiol2024;83:741-51

[35] Perhonen MA,Lane LD.Cardiac atrophy after bed rest and spaceflight.J Appl Physiol2001;91:645-53

[36] Chow GV,Fleg JL.Epidemiology of arrhythmias and conduction disorders in older adults.Clin Geriatr Med2012;28:539-53 PMCID:PMC3483564

[37] Mesquita T,Cho JH.Mechanisms of sinoatrial node dysfunction in heart failure with preserved ejection fraction.Circulation2022;145:45-60 PMCID:PMC9083886

[38] Andersen ØS,Boe E.Left bundle branch block increases left ventricular diastolic pressure during tachycardia due to incomplete relaxation.J Appl Physiol2020;128:729-38

[39] Meyer M.Heart rate and heart failure with preserved ejection fraction: time to slow β-blocker use?.Circ Heart Fail2019;12:e006213 PMCID:PMC6750011

[40] Lakatta EG.Cardiovascular regulatory mechanisms in advanced age.Physiol Rev1993;73:413-67

[41] Ostchega Y,Hughes J,Nwankwo T.Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008.Natl Health Stat Rep2011;41:1-16 PMCID:PMC7428080

[42] Gillum RF.Epidemiology of resting pulse rate of persons ages 25-74-data from NHANES 1971-74.Public Health Rep1992;107:193-201 PMCID:PMC1403631

[43] Drazner MH.The progression of hypertensive heart disease.Circulation2011;123:327-34

[44] Borlaug BA,Russell SD.Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.Circulation2006;114:2138-47

[45] Hall JE,da Silva AA,Hall ME.Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.Circ Res2015;116:991-1006 PMCID:PMC4363087

[46] Russo C,Homma S.Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort.J Am Coll Cardiol2011;57:1368-74 PMCID:PMC3077126

[47] Wright JT Jr,Whelton PK.A randomized trial of intensive versus standard blood-pressure control.N Engl J Med2015;373:2103-16 PMCID:PMC4689591

[48] Soliman EZ,Zhang ZM.Effect of intensive blood pressure lowering on the risk of atrial fibrillation.Hypertension2020;75:1491-6 PMCID:PMC7225060

[49] Solomon SD,Anand IS.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.N Engl J Med2019;381:1609-20

[50] Anker SD,Filippatos G.Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med2021;385:1451-61

[51] Jastreboff AM,Ahmad NN.Tirzepatide once weekly for the treatment of obesity.N Engl J Med2022;387:205-16

[52] Solomon SD,Claggett B.Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N Engl J Med2022;387:1089-98

[53] Jastreboff AM,Frías JP.Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial.N Engl J Med2023;389:514-26

[54] Kosiborod MN,Borlaug BA.Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N Engl J Med2023;389:1069-84

[55] Shen MJ,Jalife J.Atrial myopathy.JACC Basic Transl Sci2019;4:640-54 PMCID:PMC6872845

[56] Meyer M,Benson L,Dahlström U.Association between β-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry.J Card Fail2021;27:1165-74 PMCID:PMC8573055

[57] Goyal P,Krishnan U.Post-operative atrial fibrillation and risk of heart failure hospitalization.Eur Heart J2022;43:2971-80 PMCID:PMC9890619

[58] Solomon SD,Claggett BL.Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial.JACC Heart Fail2022;10:184-97

[59] Shah SJ,Borlaug BA.Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap.Circulation2016;134:73-90 PMCID:PMC4930115

[60] Kittleson MM,Ambardekar AV.2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the american college of cardiology solution set oversight committee.J Am Coll Cardiol2023;81:1076-126

[61] Sipe JD,Buxbaum JN.Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.Amyloid2016;23:209-13

[62] González-López E,Guzzo-Merello G.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur Heart J2015;36:2585-94

[63] Kitzman DW,Tomczak CR.Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction.Circ Heart Fail2017;10:e004281 PMCID:PMC5546154

[64] Shah SJ,Kitzman DW.Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary.Circulation2020;141:1001-26 PMCID:PMC7101072

[65] Paulus WJ.A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol2013;62:263-71

[66] Hahn VS,Luo X.Myocardial gene expression signatures in human heart failure with preserved ejection fraction.Circulation2021;143:120-34

[67] Ye B,Abrahante JE.Left ventricular gene expression in heart failure with preserved ejection fraction-profibrotic and proinflammatory pathways and genes.Circ Heart Fail2023;16:e010395 PMCID:PMC10430768

[68] Liu CY,Wu C.Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (multi-ethnic study of atherosclerosis).J Am Coll Cardiol2013;62:1280-7 PMCID:PMC3807823

[69] Mohammed SF,Mirzoyev SA,Maleszewski JJ.Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.Circulation2015;131:550-9 PMCID:PMC4324362

[70] Fraticelli A,Danziger R,Spurgeon H.Morphological and contractile characteristics of rat cardiac myocytes from maturation to senescence.Am J Physiol1989;257:H259-65

[71] Janczewski AM.Modulation of sarcoplasmic reticulum Ca²⁺ cycling in systolic and diastolic heart failure associated with aging.Heart Fail Rev2010;15:431-45 PMCID:PMC2945822

[72] Biernacka A.Aging and cardiac fibrosis.Aging Dis2011;2:158-73 PMCID:PMC3153299

[73] Ferrucci L.Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.Nat Rev Cardiol2018;15:505-22 PMCID:PMC6146930

[74] Zile MR,Ikonomidis JS.Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.Circulation2015;131:1247-59 PMCID:PMC4390480

[75] Messias LR,de Miranda SM.Abnormal adrenergic activation is the major determinant of reduced functional capacity in heart failure with preserved ejection fraction.Int J Cardiol2016;203:900-2

[76] van Heerebeek L,Niessen HW.Myocardial structure and function differ in systolic and diastolic heart failure.Circulation2006;113:1966-73

[77] Borbély A,van Heerebeek L.Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium.Circ Res2009;104:780-6

[78] Andersen MJ,Kane GC.Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.Circ Heart Fail2015;8:542-50

[79] Shah AM,Prasad N.Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction.J Am Coll Cardiol2019;74:2858-73

[80] Sarma S,Hendrix J.Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction.Circ Heart Fail2020;13:e006331 PMCID:PMC7347285

[81] Palau P,Domínguez E.Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction.J Am Coll Cardiol2021;78:2042-56

[82] Nanayakkara S,Mak V,Dean E.Extended-release oral milrinone for the treatment of heart failure with preserved ejection fraction.J Am Heart Assoc2020;9:e015026 PMCID:PMC7670502

[83] Kaye DM,Vizi D,Mariani JA.Effects of milrinone on rest and exercise hemodynamics in heart failure with preserved ejection fraction.J Am Coll Cardiol2016;67:2554-6

[84] Burkhoff D,Shah SJ.Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial.JACC Heart Fail2021;9:360-70

[85] Aiad N,Zhang MJ.Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial. ESC Heart Fail 2024.

[86] Redfield MM,Borlaug BA.Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.JAMA2013;309:1268-77

[87] Zile MR,Gaasch WH.Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle.N Engl J Med2004;350:1953-9

[88] Eisner DA,Trafford AW.The control of diastolic calcium in the heart: basic mechanisms and functional implications.Circ Res2020;126:395-412 PMCID:PMC7004450

[89] Luo W,Harrer J.Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation.Circ Res1994;75:401-9

[90] Meyer M,He H.Phospholamban-to-SERCA2 ratio controls the force-frequency relationship.Am J Physiol1999;276:H779-85

[91] Shah AM,Sweitzer NK.Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone.Circulation2015;132:402-14 PMCID:PMC4526442

[92] Mulieri LA,Leavitt B,Alpert NR.Altered myocardial force-frequency relation in human heart failure.Circulation1992;85:1743-50

[93] Pieske B,Meyer M.Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy.Circulation1995;92:1169-78

[94] Tamargo M,Espinosa MÁ.Increased chamber resting tone is a key determinant of left ventricular diastolic dysfunction.Circ Heart Fail2023;16:e010673 PMCID:PMC10729900

[95] Kagami K,Harada T.Diastolic filling time, chronotropic response, and exercise capacity in heart failure and preserved ejection fraction with sinus rhythm.J Am Heart Assoc2022;11:e026009 PMCID:PMC9333393

[96] Leite-Moreira AF,Gillebert TC.Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction.Cardiovasc Res1999;43:344-53

[97] Prinzen FW,Mullens W,Huizar JF.Electrical management of heart failure: from pathophysiology to treatment.Eur Heart J2022;43:1917-27 PMCID:PMC9123241

[98] Williams Jr JF,Fowler MB.Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Committee on Evaluation and Management of Heart Failure).Circulation1995;92:2764-84

[99] Meyer M,LeWinter M.Pharmacological heart rate lowering in patients with a preserved ejection fraction-review of a failing concept.Heart Fail Rev2018;23:499-506 PMCID:PMC5934348

[100] Wilcox JE,Vallakati A,Shah SJ.Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction.Am J Cardiol2011;108:1760-6 PMCID:PMC3637899

[101] Santos AB,Bello N.Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.Eur Heart J2014;35:42-7 PMCID:PMC6279198

[102] Backhaus SJ,Schulz A.Cardiovascular magnetic resonance rest and exercise-stress left atrioventricular coupling index to detect diastolic dysfunction.Am J Physiol Heart Circ Physiol2023;324:H686-95

[103] Infeld M,Cicero J.Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: design and rationale for the myPACE randomized controlled trial.Heart Rhythm O22022;3:109-16 PMCID:PMC8859799

[104] Wachtell K,Gerdts E.Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan intervention for end point reduction in hypertension (LIFE) study.J Am Coll Cardiol2005;45:712-9

[105] Fox K,Steg PG,Tendera M.Ivabradine in stable coronary artery disease without clinical heart failure.N Engl J Med2014;371:1091-9

[106] Habel N,Infeld M.Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation.Int J Cardiol Cardiovasc Risk Prev2023;17:200182 PMCID:PMC9996284

[107] Xiao RP,Wang DJ.Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases.J Clin Invest1998;101:1273-82

[108] Lorenzo M,Palau P.Lower heart rate in patients with acute heart failure: the role of left ventricular ejection fraction.Scand Cardiovasc J2024;58:2386977

[109] Anker SD,Filippatos G.Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial.Eur J Heart Fail2020;22:2383-92

[110] Infeld M,Wahlberg K.An approach towards individualized lower rate settings for pacemakers.Heart Rhythm O22020;1:390-3 PMCID:PMC7889012

[111] Meyer M,Habel N.Personalized accelerated physiologic pacing.Eur Heart J Suppl2023;25:G33-43 PMCID:PMC10637836

[112] Meyer M.Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.Europace2023;25:260-2

[113] Heidenreich PA,Aguilar D.2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.JACC2022;79:1757-80

[114] Abraham WT,Bourge RC.Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.Lancet2011;377:658-66

[115] The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).JAMA2002;288:2981-97

[116] Pitt B,Assmann SF.Spironolactone for heart failure with preserved ejection fraction.N Engl J Med2014;370:1383-92

[117] Solomon SD,Vaduganathan M.Finerenone in heart failure with mildly reduced or preserved ejection fraction.N Engl J Med2024;391:1475-85

[118] Kotecha D,Gill SK.Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial.JAMA2020;324:2497-508

[119] Al Saikhan L, Chaturvedi N, Ghosh AK, Hardy R, Hughes A. Adulthood adiposity affects cardiac structure and function in later life.Eur Heart J2024;45:3060-8 PMCID:PMC11365607

[120] Meyer M,Zile MR.A targeted treatment opportunity for HFpEF: taking advantage of diastolic tone.Circulation2021;144:1269-71

[121] Packer M,Rodeheffer RJ.Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group.N Engl J Med1991;325:1468-75

[122] Hiatt WR,Brass EP.Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects).J Vasc Surg2008;47:330-6

[123] McHutchison C,Appleton JP.Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis.Stroke2020;51:2374-85 PMCID:PMC7382534

[124] Infeld M,Sánchez-Quintana D.Physiological pacing for the prevention and treatment of heart failure: a state-of-the-art review.J Card Fail2024;30:1614-28

[125] Infeld M,Cicero J.Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial.JAMA Cardiol2023;8:213-21 PMCID:PMC9996402

[126] Wahlberg KJ,Plante TB.Effects of continuous accelerated pacing on cardiac structure and function in patients with heart failure with preserved ejection fraction: insights from the myPACE randomized clinical trial.J Am Heart Assoc2024;13:e032873 PMCID:PMC10863817

[127] Klein FJ,Runte KE.Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept.Am J Physiol Heart Circ Physiol2016;311:H1031-9 PMCID:PMC5114468

[128] Riaz S,Stockey K,Weissler-Snir A.Effect of personalized accelerated pacing in patients with nonobstructive hypertrophic cardiomyopathy.J Am Coll Cardiol2024;83:1492-3

[129] van Loon T, Rijks J, van Koll J, et al. Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study.Eur Heart J2024;45:4953-64 PMCID:PMC11631061

[130] Meyer M.Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?.Eur Heart J2024;45:4965-7

[131] Shah SJ,Chung ES.Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.Lancet2022;399:1130-40

[132] Stone GW,Rodés-Cabau J.Interatrial shunt treatment for heart failure: the randomized RELIEVE-HF trial.Circulation2024;150:1931-43

[133] Fudim M,Borlaug BA.Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: rationale, design and lead-in phase results of the REBALANCE-HF trial.J Card Fail2024;30:877-89

[134] Ridker PM,Thuren T.Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med2017;377:1119-31

[135] Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.Circ Res2001;89:445-52

[136] Lorenz M,Owens D.Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.Cardiovasc Diabetol2017;16:6 PMCID:PMC5237337